Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial

Background: Glucosamine, chondroitinsulfate are frequently used to prevent further joint degeneration in osteoarthritis (OA). Methylsulfonylmethane (MSM) is a supplement containing organic sulphur and also reported to slow anatomical joint progressivity in the knee OA. The MSM is often combined with...

Full description

Saved in:
Bibliographic Details
Main Authors: Andri M.T. Lubis, Carles Siagian, Erick Wonggokusuma, Aldo F Marsetyo, Bambang Setyohadi
Format: Article
Language:English
Published: Interna Publishing 2017-08-01
Series:Acta Medica Indonesiana
Subjects:
Online Access:https://actamedindones.org/index.php/ijim/article/view/168
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850059551771983872
author Andri M.T. Lubis
Carles Siagian
Erick Wonggokusuma
Aldo F Marsetyo
Bambang Setyohadi
author_facet Andri M.T. Lubis
Carles Siagian
Erick Wonggokusuma
Aldo F Marsetyo
Bambang Setyohadi
author_sort Andri M.T. Lubis
collection DOAJ
description Background: Glucosamine, chondroitinsulfate are frequently used to prevent further joint degeneration in osteoarthritis (OA). Methylsulfonylmethane (MSM) is a supplement containing organic sulphur and also reported to slow anatomical joint progressivity in the knee OA. The MSM is often combined with glucosamine and chondroitin sulfate. However, there are controversies whether glucosamine-chondroitin sulfate or their combination with methylsulfonylmethane could effectively reduce pain in OA. This study is aimed to compare clinical outcome of glucosamine-chondroitin sulfate (GC), glucosamine-chondroitin sulfate-methylsulfonylmethane (GCM), and placeboin patients with knee osteoarthritis (OA) Kellgren-Lawrence grade I-II. Methods: a double blind, randomized controlled clinical trial was conducted on 147 patients with knee OA Kellgren-Lawrence grade I-II. Patients were allocated by permuted block randomization into three groups: GC (n=49), GCM (n=50), or placebo (n=48) groups. GC group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of saccharumlactis; GCM group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of MSM; while placebo group received three matching capsules of saccharumlactis. The drugs were administered once daily for 3 consecutive months VAS and WOMAC scores were measured before treatment, then at 4th, 8th and 12th week after treatment. Results: on statistical analysis it was found that at the 12th week, there are significant difference between three treatment groups on the WOMAC score (p=0.03) and on the VAS score (p=0.004). When analyzed between weeks, GCM treatment group was found statistically significant on WOMAC score (p=0.01) and VAS score (p<0.001). Comparing the score difference between weeks, WOMAC score analysis showed significant difference between GC, GCM, and placebo in week 4 (p=0.049) and week 12 (p=0.01). In addition, VAS score also showed significant difference between groups in week 8 (p=0.006) and week 12 (p<0.001). Conclusion: combination of glucosamine-chondroitinsulfate-methylsulfonylmethane showed clinical benefit for patients with knee OAK ellgren-Lawrence grade I-II compared with GC and placebo. GC did not make clinical improvement in overall groups of patients with knee OA Kellgren Lawrence grade I-II.
format Article
id doaj-art-d092911dfd97429bbbe4e82de1375e97
institution DOAJ
issn 0125-9326
2338-2732
language English
publishDate 2017-08-01
publisher Interna Publishing
record_format Article
series Acta Medica Indonesiana
spelling doaj-art-d092911dfd97429bbbe4e82de1375e972025-08-20T02:50:52ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322017-08-01492Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled TrialAndri M.T. Lubis0Carles Siagian1Erick Wonggokusuma2Aldo F Marsetyo3Bambang Setyohadi4Department of Orthopaedic Surgery, Faculty of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.Department of Orthopaedic Surgery, Faculty of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.Department of Orthopaedic Surgery, Faculty of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.Department of Orthopaedic and Traumatology, Faculty of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Jakarta, IndonesiaDepartment of Internal Medicine, Faculty of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.Background: Glucosamine, chondroitinsulfate are frequently used to prevent further joint degeneration in osteoarthritis (OA). Methylsulfonylmethane (MSM) is a supplement containing organic sulphur and also reported to slow anatomical joint progressivity in the knee OA. The MSM is often combined with glucosamine and chondroitin sulfate. However, there are controversies whether glucosamine-chondroitin sulfate or their combination with methylsulfonylmethane could effectively reduce pain in OA. This study is aimed to compare clinical outcome of glucosamine-chondroitin sulfate (GC), glucosamine-chondroitin sulfate-methylsulfonylmethane (GCM), and placeboin patients with knee osteoarthritis (OA) Kellgren-Lawrence grade I-II. Methods: a double blind, randomized controlled clinical trial was conducted on 147 patients with knee OA Kellgren-Lawrence grade I-II. Patients were allocated by permuted block randomization into three groups: GC (n=49), GCM (n=50), or placebo (n=48) groups. GC group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of saccharumlactis; GCM group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of MSM; while placebo group received three matching capsules of saccharumlactis. The drugs were administered once daily for 3 consecutive months VAS and WOMAC scores were measured before treatment, then at 4th, 8th and 12th week after treatment. Results: on statistical analysis it was found that at the 12th week, there are significant difference between three treatment groups on the WOMAC score (p=0.03) and on the VAS score (p=0.004). When analyzed between weeks, GCM treatment group was found statistically significant on WOMAC score (p=0.01) and VAS score (p<0.001). Comparing the score difference between weeks, WOMAC score analysis showed significant difference between GC, GCM, and placebo in week 4 (p=0.049) and week 12 (p=0.01). In addition, VAS score also showed significant difference between groups in week 8 (p=0.006) and week 12 (p<0.001). Conclusion: combination of glucosamine-chondroitinsulfate-methylsulfonylmethane showed clinical benefit for patients with knee OAK ellgren-Lawrence grade I-II compared with GC and placebo. GC did not make clinical improvement in overall groups of patients with knee OA Kellgren Lawrence grade I-II.https://actamedindones.org/index.php/ijim/article/view/168Glucosaminechondroitin sulfatemethylsufonylmethaneosteoarthritis
spellingShingle Andri M.T. Lubis
Carles Siagian
Erick Wonggokusuma
Aldo F Marsetyo
Bambang Setyohadi
Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial
Acta Medica Indonesiana
Glucosamine
chondroitin sulfate
methylsufonylmethane
osteoarthritis
title Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial
title_full Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial
title_fullStr Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial
title_full_unstemmed Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial
title_short Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial
title_sort comparison of glucosamine chondroitin sulfate with and without methylsulfonylmethane in grade i ii knee osteoarthritis a double blind randomized controlled trial
topic Glucosamine
chondroitin sulfate
methylsufonylmethane
osteoarthritis
url https://actamedindones.org/index.php/ijim/article/view/168
work_keys_str_mv AT andrimtlubis comparisonofglucosaminechondroitinsulfatewithandwithoutmethylsulfonylmethaneingradeiiikneeosteoarthritisadoubleblindrandomizedcontrolledtrial
AT carlessiagian comparisonofglucosaminechondroitinsulfatewithandwithoutmethylsulfonylmethaneingradeiiikneeosteoarthritisadoubleblindrandomizedcontrolledtrial
AT erickwonggokusuma comparisonofglucosaminechondroitinsulfatewithandwithoutmethylsulfonylmethaneingradeiiikneeosteoarthritisadoubleblindrandomizedcontrolledtrial
AT aldofmarsetyo comparisonofglucosaminechondroitinsulfatewithandwithoutmethylsulfonylmethaneingradeiiikneeosteoarthritisadoubleblindrandomizedcontrolledtrial
AT bambangsetyohadi comparisonofglucosaminechondroitinsulfatewithandwithoutmethylsulfonylmethaneingradeiiikneeosteoarthritisadoubleblindrandomizedcontrolledtrial